Acasti Pharma (ACST)
(Delayed Data from NSDQ)
$3.18 USD
+0.02 (0.63%)
Updated Jun 12, 2024 12:03 PM ET
After-Market: $3.25 +0.07 (2.20%) 7:58 PM ET
3-Hold of 5 3
F Value A Growth D Momentum C VGM
Brokerage Reports
Acasti Pharma, Inc. [ACST]
Reports for Purchase
Showing records 21 - 40 ( 43 total )
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Top Picks Portfolio - Q319 Performance, Q419 Introduction
Provider: Echelon Welath Partners
Analyst: GOFF R
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Ascribing Top Pick Status To Phase III-Stage Omega-3 Drug Developer.
Provider: Echelon Welath Partners
Analyst: LOE D
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
FQ120 Update Shows CaPre Still Advancing Toward Seminal Phase III Inflection Point By End-Of-Year - Spec BUY
Provider: Echelon Welath Partners
Analyst: LOE D
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Phase 3 TRILOGY Progress, CaPre Remains on Track for Topline Data in December 2019; Reit Buy and $6 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
Company: Acasti Pharma, Inc.
Industry: Medical - Generic Drugs
We are initiating coverage with a BUY rating
Provider: DAWSON JAMES SECURITIES, INC.
Analyst: WASSERMAN R